Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2015.

The Company reported a net loss of $2.7 million for the second quarter 2015 or $0.05 per diluted share, compared to net loss of$3.5 million or $0.07 per diluted share for the same period in 2014. Revenues for the quarter were $0.3 million compared to $35 thousand in the second quarter of 2014.

Research and development expenses associated with product candidates utilizing the Company’s LIMITX™, and IMPEDE® Technologies were $0.5 million in the second quarter 2015, compared to $1.3 million for the same period in 2014. Selling, marketing, general and administrative expenses were $2.1 million in the second quarter 2015, versus $1.9 million in the same period last year. Selling and marketing expenses primarily consist of advertising and marketing activities for NEXAFED® and NEXAFED® SINUS.

The Company reported a net loss of $1.4 million for the six months ended June 30, 2015 or $0.03 per diluted share, compared to net loss of $7.6 million or $0.16 per diluted share for the same period in 2014. Revenues for the six months ended June 30, 2015were $5.7 million compared to $77 thousand in the same period last year. The 2015 results reflect the $5.0 million payment arising from licensing OXAYDO™ to Egalet Corporation entities.

Research and development expenses associated with product candidates utilizing the Company’s LIMITX™, and IMPEDE® Technologies were $1.5 million in the six months ended June 30, 2015, compared to $2.7 million for the same period in 2014 for the Company’s LIMITX™, AVERSION® and IMPEDE® Technologies. Selling, marketing, general and administrative expenses were $4.4 million in the six months ended June 30, 2015, versus $4.2 million in the same period last year. Selling and marketing expenses primarily consisted of advertising and marketing activities for NEXAFED® and NEXAFED® SINUS.

As of July 30, 2015, our unrestricted cash, cash equivalents and marketable securities, less our compensating balance requirement of $2.5 million, was approximately $14.9 million, and our gross term debt financing was $9.23 million. (Original Source)

Shares of Acura closed today at $0.76, down $0.025 or 3.18%. ACUR has a 1-year high of $1.35 and a 1-year low of $0.41. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $0.76.

On the ratings front, MLV & Co. analyst Vernon Bernardino reiterated a Buy rating on ACUR, with a price target of $2, in a report issued on July 1. The current price target represents a potential upside of 163.2% from where the stock is currently trading. According to TipRanks.com, Bernardino has a total average return of -9.8%, a 32.3% success rate, and is ranked #3627 out of 3724 analysts.

Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of productto address medication abuse & misuse, utilizing the Company’s proprietary, tamper-resistant AVERSION& IMPEDEtechnology platforms.